Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 187

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study

Open access
Montalescot, G., Pitt, B., Lopez de Sa, E., Hamm, C. W., Flather, M., Verheugt, F., Shi, H., Turgonyi, E., Orri, M., Vincent, J., Zannad, F., for the REMINDER Investigators, Noll, G., Weir, R., O'Neill, B., Bohm, M., Hillis, W. S., Grieve, A., Rouleau, J.-L., Gerasimos, F., Fitchett, D., Lepage, S., Madan, M., Sussex, B., Tremblay, G., Welsh, R., Wong, G., Hutyra, M., Kettner, J., Ostadal, P., Spinar, J., Vojacek, J., Barboteu, M., Collet, J.-P., Coste, P., Cottin, Y., Ducos, D., Galinier, M., Teiger, E., Zemour, G., Bauersachs, J., Hambrecht, R., Hauf, G., Heuer, H., Mudra, H., Munzel, T., Steiner, S., Strasser, R., Sydow, K., Tschope, C., Wachter, R., Werner, N., Alexopoulos, D., Babalis, D., Pyrgakis, V., Dezsi, C., Lupkovics, G., Polgar, P., Tomcsanyi, J., Herrman, J., ten Berg, J. M., Gorny, J., Kubica, J., Lewczuk, J., Zmuda, W., Hranai, M., Kovar, F., Margoczy, R., Micko, K., Sumbal, J., Genover, X. B., Ortiz, A. F., Sala, M. F., Garcia, C. G., Munoz, C. P., Rey Blas, J. R., Soriano, F. R., Adamson, D., Alamgir, F., Chauhan, A., Lip, G., Martin, T., McCann, G., Newby, D., Smith, D.·2014·European Heart Journal

Abstract

AIMS: We aimed to assess the impact of eplerenone on cardiovascular (CV) outcomes in STEMI without known heart failure, when initiated within 24 h of symptom onset. METHODS AND RESULTS: In this randomized, placebo-controlled, double-blind trial, we assigned 1012 patients with acute STEMI and without a history of heart failure to receive either eplerenone (25-50 mg once daily) or placebo in addition to standard therapy. The primary endpoint was the composite of CV mortality, re-hospitalization, or, extended initial hospital stay, due to diagnosis of HF, sustained ventricular tachycardia or fibrillation, ejection fraction ≤40%, or elevated BNP/NT-proBNP at 1 month or more after randomization. BNP elevation was defined as BNP levels or values above 200 pg/mL or NT-proBNP values above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) or above 1800 pg/mL (patients older than 75). After a mean follow-up of 10.5 months, the primary endpoint occurred in 92 patients (18.2%) in the eplerenone group and in 149 patients (29.4%) in the placebo group [adjusted hazard ratio (HR), 0.58; 95% confidence interval (CI), 0.45-0.76; P < 0.0001]. The primary endpoint was driven by a high BNP/NT-proBNP level (adjusted HR, 0.60; 95% CI, 0.45-0.79; P < 0.0003). Adverse event rates were similar in both groups. Serum potassium levels exceeded 5.5 mmol/L in 5.6 vs. 3.2% (P = 0.09) and were below 3.5 mmol/L in 1.4 vs. 5.6% of patients (P = 0.0002), in the eplerenone and placebo groups, respectively. CONCLUSION: The addition of eplerenone during the acute phase of STEMI was safe and well tolerated. It reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels. Additional studies are needed to clarify the role of early use of MRAs in STEMI patients without heart failure. CLINICAL TRIAL REGISTRATION: NCT01176968.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu164

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 187

Metadata

Authors
Montalescot, G., Pitt, B., Lopez de Sa, E., Hamm, C. W., Flather, M., Verheugt, F., Shi, H., Turgonyi, E., Orri, M., Vincent, J., Zannad, F., for the REMINDER Investigators, Noll, G., Weir, R., O'Neill, B., Bohm, M., Hillis, W. S., Grieve, A., Rouleau, J.-L., Gerasimos, F., Fitchett, D., Lepage, S., Madan, M., Sussex, B., Tremblay, G., Welsh, R., Wong, G., Hutyra, M., Kettner, J., Ostadal, P., Spinar, J., Vojacek, J., Barboteu, M., Collet, J.-P., Coste, P., Cottin, Y., Ducos, D., Galinier, M., Teiger, E., Zemour, G., Bauersachs, J., Hambrecht, R., Hauf, G., Heuer, H., Mudra, H., Munzel, T., Steiner, S., Strasser, R., Sydow, K., Tschope, C., Wachter, R., Werner, N., Alexopoulos, D., Babalis, D., Pyrgakis, V., Dezsi, C., Lupkovics, G., Polgar, P., Tomcsanyi, J., Herrman, J., ten Berg, J. M., Gorny, J., Kubica, J., Lewczuk, J., Zmuda, W., Hranai, M., Kovar, F., Margoczy, R., Micko, K., Sumbal, J., Genover, X. B., Ortiz, A. F., Sala, M. F., Garcia, C. G., Munoz, C. P., Rey Blas, J. R., Soriano, F. R., Adamson, D., Alamgir, F., Chauhan, A., Lip, G., Martin, T., McCann, G., Newby, D., & Smith, D.
Venue
European Heart Journal
Published
2014-04-29
Volume
35
Issue
34
Pages
2295-2302
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2097773873
Cited by
187
References
1
FWCI
10.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. https://app.cochat.ai/papers/10.1093/eurheartj/ehu164
The paper
Montalescot, G., Pitt, B., Lopez de Sa, E., Hamm, C. W., Flather, M., Verheugt, F., Shi, H., Turgonyi, E., Orri, M., Vincent, J., Zannad, F., for the REMINDER Investigators, Noll, G., Weir, R., O'Neill, B., Bohm, M., Hillis, W. S., Grieve, A., Rouleau, J.-L., . . . Smith, D. (2014). Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.